2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 795

Characteristics and Treatment Outcomes of Giant Cell Arteritis with Large-Vessel Lesions in a Nationwide, Retrospective Cohort Study in Japan
Abstract Number: 1525

Characteristics and Treatment Patterns Among Patients with Psoriatic Arthritis Initiating Subcutaneously Administered Biologics: Descriptive Analyses from a US Claims Database
Abstract Number: 709

Characteristics of Cardiac Diseases in Systemic Lupus Erythematosus and Risk Factors of Different Echocardiographic Features
Abstract Number: 2519

Characteristics of Eye Diseases in Patients with Ankylosing Spondylitis in Korea: A Single-Center Survey
Abstract Number: 1493

Characteristics of Korean Primary Sjogren’s Syndrome and Comparison of 3 Different Classification Criteria for Primary Sjogren’s Syndrome: Data from Korean Kiss Cohort
Abstract Number: 1419

Characteristics of Patients with Early Rheumatoid Arthritis Who Have a Delayed Response to Treatment with Methotrexate in Monotherapy or in Combination with Adalimumab
Abstract Number: 1382

Characteristics of Patients with Rheumatoid Arthritis and Atlanto-Axial Pannus
Abstract Number: 2988

Characteristics of People with Work-Related Versus Non-Work Related Carpal Tunnel Syndrome: National Health Interview Survey, 2010 & 2015
Abstract Number: 435

Characteristics of Rheumatoid Arthritis Patients Who Have a DMARD Interruption and the Impact of Using a Bridging Medication on Clinical and Patient Reported Outcomes
Abstract Number: 2173

Characteristics Unique to MDA5 and Anti-Ro/SSA-52 Kda Dual Antibody Positive Patients with Inflammatory Myopathies
Abstract Number: 2345

Characterization of Adenosine Deaminase 2 Variants Identified in an International Pediatric Vasculitis Cohort
Abstract Number: 603

Characterization of Clinical Benefits in Subjects Classified As ACR20 Non-Responders at Week 104 of Apremilast Treatment: Subanalysis of 3 Long-Term, Phase III Trials
Abstract Number: 2627

Characterization of Emergency Department Visits in an Urban Underserved Lupus Cohort
Abstract Number: 1064

Characterization of Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor and Induction from Patients with Autoimmune Diseases
Abstract Number: 290

Characterization of Neutrophil Subsets and Neutrophil Extracellular Traps in Pyogenic Arthritis, Pyoderma Gangrenosum and Acne (PAPA) Syndrome

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].